Walleye Capital LLC Altimmune, Inc. Transaction History

Walleye Capital LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$5.91 - $10.23 $69,814 - $120,846	-11,813 Reduced 33.93%	23,000 $152,000
Q1 2024 May 15, 2024	BUY	$8.22 - $13.81 $92,113 - $154,754	11,206 Added 47.47%	34,813 $354,000
Q4 2023 Feb 14, 2024	BUY	$2.14 - $11.62 $50,518 - $274,313	23,607 New	23,607 $265,000
Q2 2023 Aug 14, 2023	BUY	$3.45 - $5.97 $1.29 Million - $2.22 Million	372,544 Added 788.64%	419,783 $1.48 Million
Q1 2023 May 15, 2023	BUY	$4.19 - $16.83 $197,931 - $795,032	47,239 New	47,239 $199,000
Q2 2022 Aug 08, 2022	SELL	$3.94 - $11.77 $302,434 - $903,465	-76,760 Reduced 36.25%	134,993 $1.58 Million
Q1 2022 May 16, 2022	BUY	$5.9 - $9.45 $822,749 - $1.32 Million	139,449 Added 192.86%	211,753 $1.29 Million
Q4 2021 Mar 03, 2022	BUY	$8.69 - $12.48 $628,321 - $902,353	72,304 New	72,304 $662,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $404M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.